AstraZeneca Believes Size Matters In Amyloidosis
The Big Pharma explains its eplontersen strategy
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
